Investors sold shares of Pfizer Inc. (NYSE:PFE) on strength during trading on Tuesday. $244.96 million flowed into the stock on the tick-up and $413.62 million flowed out of the stock on the tick-down, for a money net flow of $168.66 million out of the stock. Of all companies tracked, Pfizer had the 0th highest net out-flow for the day. Pfizer traded up $0.61 for the day and closed at $35.28

Several research analysts recently weighed in on the stock. BMO Capital Markets set a $39.00 target price on shares of Pfizer and gave the company a “buy” rating in a research note on Tuesday, January 30th. SunTrust Banks reaffirmed a “hold” rating and set a $40.00 price objective (up previously from $33.00) on shares of Pfizer in a research note on Monday, January 29th. Societe Generale set a $40.00 price objective on shares of Pfizer and gave the company a “neutral” rating in a research note on Wednesday, January 31st. Morgan Stanley set a $43.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Finally, UBS Group set a $42.00 price objective on shares of Pfizer and gave the company a “buy” rating in a research note on Wednesday, January 31st. Two equities research analysts have rated the stock with a sell rating, ten have issued a hold rating and eleven have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and a consensus price target of $39.45.

The company has a debt-to-equity ratio of 0.56, a current ratio of 1.43 and a quick ratio of 1.15. The company has a market capitalization of $204,930.00, a price-to-earnings ratio of 9.75, a PEG ratio of 2.12 and a beta of 0.94.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, January 30th. The biopharmaceutical company reported $0.62 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.56 by $0.06. Pfizer had a return on equity of 26.86% and a net margin of 40.55%. The business had revenue of $13.70 billion during the quarter, compared to analysts’ expectations of $13.67 billion. During the same quarter in the previous year, the business earned $0.47 EPS. The company’s revenue for the quarter was up .6% on a year-over-year basis. analysts anticipate that Pfizer Inc. will post 2.95 earnings per share for the current year.

The company also recently announced a quarterly dividend, which will be paid on Thursday, March 1st. Stockholders of record on Friday, February 2nd will be issued a dividend of $0.34 per share. The ex-dividend date is Thursday, February 1st. This represents a $1.36 dividend on an annualized basis and a dividend yield of 3.96%. This is a boost from Pfizer’s previous quarterly dividend of $0.32. Pfizer’s payout ratio is presently 38.64%.

Pfizer announced that its Board of Directors has initiated a share buyback program on Monday, December 18th that permits the company to buyback $10.00 billion in shares. This buyback authorization permits the biopharmaceutical company to buy shares of its stock through open market purchases. Stock buyback programs are generally a sign that the company’s board believes its shares are undervalued.

In other Pfizer news, insider Alexander R. Mackenzie sold 6,750 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.00, for a total value of $249,750.00. Following the completion of the transaction, the insider now owns 103,458 shares in the company, valued at approximately $3,827,946. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Rady A. Johnson sold 8,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was sold at an average price of $37.07, for a total value of $296,560.00. Following the completion of the transaction, the executive vice president now owns 46,963 shares of the company’s stock, valued at approximately $1,740,918.41. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. raised its position in shares of Pfizer by 2.3% during the 2nd quarter. Vanguard Group Inc. now owns 418,639,111 shares of the biopharmaceutical company’s stock valued at $14,062,088,000 after acquiring an additional 9,239,499 shares in the last quarter. Ameriprise Financial Inc. raised its position in shares of Pfizer by 4.4% during the 3rd quarter. Ameriprise Financial Inc. now owns 59,844,024 shares of the biopharmaceutical company’s stock valued at $2,136,189,000 after acquiring an additional 2,502,659 shares in the last quarter. Franklin Resources Inc. raised its position in shares of Pfizer by 0.9% during the 2nd quarter. Franklin Resources Inc. now owns 46,167,213 shares of the biopharmaceutical company’s stock valued at $1,550,754,000 after acquiring an additional 389,629 shares in the last quarter. Dimensional Fund Advisors LP raised its position in shares of Pfizer by 4.8% during the 2nd quarter. Dimensional Fund Advisors LP now owns 44,286,544 shares of the biopharmaceutical company’s stock valued at $1,487,617,000 after acquiring an additional 2,028,313 shares in the last quarter. Finally, Fisher Asset Management LLC raised its position in shares of Pfizer by 3.6% during the 4th quarter. Fisher Asset Management LLC now owns 36,372,349 shares of the biopharmaceutical company’s stock valued at $1,317,407,000 after acquiring an additional 1,251,550 shares in the last quarter. Hedge funds and other institutional investors own 69.87% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “Investors Sell Shares of Pfizer (PFE) on Strength (PFE)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US & international trademark & copyright law. The legal version of this article can be read at https://www.thecerbatgem.com/2018/02/08/investors-sell-shares-of-pfizer-pfe-on-strength-pfe.html.

Pfizer Company Profile

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.